This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shiffman, F. Articles by Prewitt, R. M. Search for Related Content PubMed PubMed Citation Articles by Shiffman, F. Articles by Prewitt, R. M. Pubmed/NCBI databases Substance via MeSH Hazardous Substances DB HEPARIN Medline Plus Health Information Pulmonary Embolism Pulmonary Hypertension

Circulation, Vol 78, 214-220, Copyright © 1988 by American Heart Association

ARTICLES

Treatment of canine embolic pulmonary hypertension with recombinant tissue plasminogen activator. Efficacy of dosing regimes

F Shiffman, J Ducas, P Hollett, E Israels, D Greenberg, R Cook and RM Prewitt
Department of Medicine, University of Manitoba Health Sciences Centre, Winnipeg, Canada.

We investigated effects of two dosing regimes of recombinant tissue plasminogen activator (rt-PA) and sodium heparin on pulmonary thrombolysis in a canine model of pulmonary hypertension, induced by injection of radioactive blood clots. By continuously counting over both lung fields with a mobile gamma camera, we correlated rate and extent of pulmonary thrombolysis with corresponding pulmonary hemodynamics. Treatment with heparin, over a 3-hour interval, did not result in significant thrombolysis or in a decrease in mean pulmonary artery pressure (PAP). In contrast, rt-PA caused marked pulmonary thrombolysis. While total clot lysis was similar when 1 mg/kg rt-PA was infused over 15 (rt-PA15) or 90 (rt-PA90) minutes (47% and 42%, respectively), rate of lysis during infusion was markedly increased with rt-PA15 (56% vs. 27%/hr, p less than 0.001). Corresponding to the increased rate of thrombolysis with rt-PA15, relative PAP decrease was greater at 15 and 30 minutes. At 4 hours, PAP decreased most with rt- PA90. However, two of the six dogs given rt-PA15 had an increase in PAP and lung radioactivity 1 hour after rt-PA. This was associated with dislodgment of a previously trapped clot. These results suggest that rt- PA may be appropriate therapy for pulmonary embolism and support further studies designed to optimize dosing regimes.

This article has been cited by other articles:

				R. B. Abu-Laban, J. M. Christenson, G. D. Innes, C. A. van Beek, K. P. Wanger, R. D. McKnight, I. A. MacPhail, J. Puskaric, R. P. Sadowski, J. Singer, et al. Tissue Plasminogen Activator in Cardiac Arrest with Pulseless Electrical Activity N. Engl. J. Med., May 16, 2002; 346(20): 1522 - 1528. [Abstract] [Full Text] [PDF]

				R. M. Prewitt, S. Gu, U. Schick, and J. Ducas Effect of Rate of Administration of Recombinant Tissue Plasminogen Activator on Efficacy of Coronary Thrombolysis Angiology, August 1, 1994; 45(8): 687 - 694. [Abstract] [PDF]